World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
86
Citations
33512
World Ranking
1238
National Ranking
647

Medicine

D-Index
86
Citations
33701
World Ranking
13951
National Ranking
7081

Mary L. Disis publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Mary L. Disis sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 455 publications — 86th percentile

86% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Mary L. Disis D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Mary L. Disis sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 86 D-Index — 75th percentile

75% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Research.com Recognitions

  • Member of the Association of American Physicians
  • Member of the Association of American Physicians
  • Member of the Association of American Physicians
  • Member of the Association of American Physicians

Overview

Mary L. Disis is affiliated with the University of Washington in the United States. Their research primarily focuses on medicine, with significant contributions across several subfields including oncology, general health professions, immunology, public health, environmental and occupational health, and molecular biology.

The main topics addressed in Mary L. Disis's research include:

  • Immunotherapy and Immune Responses
  • Cancer Immunotherapy and Biomarkers
  • Healthcare cost, quality, practices
  • Health and Medical Research Impacts
  • Health Sciences Research and Education
  • Artificial Intelligence in Healthcare and Education
  • Ethics in Clinical Research

Mary L. Disis has published extensively in high-impact journals. Frequent publication venues include:

  • JAMA Oncology (10 publications)
  • Cancer Research (9 publications)
  • Regular and Young Investigator Award Abstracts (8 publications)
  • Journal for ImmunoTherapy of Cancer (6 publications)
  • JAMA (6 publications)

Representative recent papers authored or coauthored by Mary L. Disis are:

  • Safety and Outcomes of a Plasmid DNA Vaccine Encoding the ERBB2 Intracellular Domain in Patients With Advanced-Stage ERBB2-Positive Breast Cancer, 2022, JAMA Oncology
  • Differentiation and Regulation of TH Cells: A Balancing Act for Cancer Immunotherapy, 2021, Frontiers in Immunology
  • Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer, 2021, Journal for ImmunoTherapy of Cancer
  • Therapeutic cancer vaccines revamping: technology advancements and pitfalls, 2021, Annals of Oncology
  • Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsets, 2020, Nature Cancer

Frequent collaborators in their publications include:

  • Robert O. Bonow
  • Dimitri Christakis
  • Jay F. Piccirillo
  • Kanade Shinkai
  • Döst Öngür

Mary L. Disis is recognized as a member of the Association of American Physicians. Their work encompasses clinical research and healthcare education, intersecting translational medicine and immunotherapy, particularly in the context of cancer treatment strategies.

Best Publications

  • Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.

    Tyler J Curiel;George Coukos;Linhua Zou;Xavier Alvarez

  • Tumor antigen-specific T helper cells in cancer immunity and immunotherapy.

    K. L. Knutson;M. L. Disis

  • Clinical significance of tumor-infiltrating lymphocytes in breast cancer

    Sasha E. Stanton;Mary L. Disis

  • Gene expression markers of Tumor Infiltrating Leukocytes

    Patrick Danaher;Sarah Warren;Lucas Dennis;Leonard D’Amico

  • Toxicities of Immunotherapy for the Practitioner

    Jeffrey S. Weber;James C. Yang;Michael B. Atkins;Mary L. Disis

  • Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer.

    Mary L. Disis;Emanuel Calenoff;Graham McLaughlin;Ann E. Murphy

  • Variation in the Incidence and Magnitude of Tumor-Infiltrating Lymphocytes in Breast Cancer Subtypes: A Systematic Review

    Sasha E. Stanton;Sylvia Adams;Mary L. Disis

  • Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients

    Keith L. Knutson;Kathy Schiffman;Mary L. Disis

  • Immune Regulation of Cancer

    Mary L. Disis

  • Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines

    Mary L. Disis;Theodore A. Gooley;Kristine Rinn;Donna Davis

  • Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine.

    Mary L. Disis;Kenneth H. Grabstein;Paul R. Sleath;Martin A. Cheever

  • Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines

    Mary L. Disis;Helga Bernhard;Faith M. Shiota;Susan L. Hand

  • High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer.

    Mary L. Disis;Serenella M. Pupa;Julie R. Gralow;Ruggero Dittadi

  • Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial.

    Mary L. Disis;Mary L. Disis;Matthew H. Taylor;Karen Kelly;J. Thaddeus Beck

  • Current Landscape of Immunotherapy in Breast Cancer: A Review

    Sylvia Adams;Margaret E. Gatti-Mays;Kevin Kalinsky;Larissa A. Korde

  • Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy.

    Ulrich Keilholz;Jeffrey Weber;James H. Finke;Dmitry I. Gabrilovich

  • Generation of Immunostimulatory Dendritic Cells from Human CD34+ Hematopoietic Progenitor Cells of the Bone Marrow and Peripheral Blood

    Helga Bernhard;Mary L. Disis;Shelly Heimfeld;Susan Hand

  • Immunization of Cancer Patients with a HER-2/neu, HLA-A2 Peptide, p369–377, Results in Short-lived Peptide-specific Immunity

    Keith L. Knutson;Kathy Schiffman;Martin A. Cheever;Mary L. Disis

  • Transcriptome-Wide Studies of Merkel Cell Carcinoma and Validation of Intratumoral CD8+ Lymphocyte Invasion As an Independent Predictor of Survival

    Kelly G. Paulson;Jayasri G. Iyer;Andrew R. Tegeder;Renee Thibodeau

  • Concurrent Trastuzumab and HER2/neu-Specific Vaccination in Patients With Metastatic Breast Cancer

    Mary L. Disis;Danelle R. Wallace;Theodore A. Gooley;Yushe Dang

  • Peptide-based, but not whole protein, vaccines elicit immunity to HER-2/neu, oncogenic self-protein.

    Mary L. Disis;Julie R. Gralow;Helga Bernhard;Susan L. Hand

Frequent Co-Authors

Keith L. Knutson
Keith L. Knutson Mayo Clinic
Martin A. Cheever
Martin A. Cheever University of Washington
Holden T. Maecker
Holden T. Maecker Stanford University
Vernon C. Maino
Vernon C. Maino Becton Dickinson (United States)
Lisa H. Butterfield
Lisa H. Butterfield University of California, San Francisco
Robert O. Bonow
Robert O. Bonow Northwestern University
Rita F. Redberg
Rita F. Redberg University of California, San Francisco
Frederick P. Rivara
Frederick P. Rivara University of Washington
Stephan Heckers
Stephan Heckers Vanderbilt University Medical Center
Neil M. Bressler
Neil M. Bressler Johns Hopkins University School of Medicine

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in Immunology, complementary careers in healthcare can expand your opportunities. Many professionals pursue advanced practice roles, such as Psychiatric Nurse Practitioners, where you can find some of the cheapest psych np programs online. These programs offer affordable pathways to specialized mental health care, which often overlaps with immunological research in neuroimmunology.

Understanding regional differences in compensation is vital when planning your future. For example, the dnp salary by state varies widely, influencing where you might choose to practice after completing your degree.

If you are a Family Nurse Practitioner considering specialization, earning an acute care np certification can open doors to advanced care roles that often involve working with immunocompromised or critically ill patients, bridging clinical care and immunology.

For Registered Nurses looking to quickly advance their careers, exploring accelerated rn to np programs can provide efficient routes to nurse practitioner roles, including specialties that complement immunology studies.

Best Scientists Citing Mary L. Disis

Trending Scientists

Recently Published Articles